SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Buy MNT (Short-Term Trade)
MNT
-60.63%
in
902 days
<> Rationale: 1) With 16% of its float sold short, or 6,537,400 million shares, with 4.3 days to cover and average daily trading volume (3m) of 888K, it will take 7.36 days to cover the entire position.
2) On a fundamental level MNT is turning around, evident by the fact that inventory levels were 150-170 days for the quarter ending May, vs. 200 and 548 days in 06 and 05. Furthermore, efficient mgmt has led to a shrinking cash conversion cycle, 110 days from 150 and 400 in 06 and 05.
<> 3) On April 20th, MNT plunged 5 points on loweri...
|
MNT is a BUY
MNT
From the Blogosphere
FDA Calendar: A Weekly Update
|
|
|
<>The accompanying table [click to enlarge] presents an updated calendar of 74 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week.
1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standard 10-month review target decision date = 10/1/09.
2.) Questcor...
|
Johnson & Johnson Steals Mentor Corp.: Who's Next?
|
<>Last Monday, Johnson & Johnson (JNJ) announced that it had agreed to acquire Mentor (MNT) for $1.07 billion or $31/share, a 92% premium to the prior day’s closing price. While this may sound like a whopping deal for MNT investors, the fact remains that JNJ stole Mentor and likely underpaid for the company. Mentor shares, already down 57% on the year, would have needed to be taken out at a 132% premium simply to match the price level at which they were trading at not too long ago. While another 30-40% on top of JNJ's offer would be great for Mentor’s long term shareholder base, don’t e<>...
|
FDA Calendar: A Weekly Update
|
|
|
<>The accompanying table [click to enlarge] presents an updated calendar of 74 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week.
1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standard 10-month review target decision date = 10/1/09.
2.) Questcor...
|
Bet on T&A with J&J (JNJ)
MNT
-47.87%
in
356 days
Filed under: Deals, Good news, Newsletters, Johnson and Johnson (JNJ), Stocks to Buy  Over the long holiday weekend, I had a chance to do some much needed reading. Given my vocation, sometimes I like to read articles that have little to do with the markets or finance as a way of recharging my batteries.
Of course, even when I partake in this guilty pleasure, there really is no way to truly escape. Somehow every story has a link or relationship to investing that I can utilize in my stock-picking mission. <>This weekend, it was an article critical of a Shape magazine cover featuring a bikini-clad F...
|
Johnson & Johnson (JNJ) buying Mentor (MNT) a good sign
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Mentor Corp.
- Answers.com
